PE20211447A1 - Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparacion y uso de las mismas - Google Patents

Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparacion y uso de las mismas

Info

Publication number
PE20211447A1
PE20211447A1 PE2020001271A PE2020001271A PE20211447A1 PE 20211447 A1 PE20211447 A1 PE 20211447A1 PE 2020001271 A PE2020001271 A PE 2020001271A PE 2020001271 A PE2020001271 A PE 2020001271A PE 20211447 A1 PE20211447 A1 PE 20211447A1
Authority
PE
Peru
Prior art keywords
unsubstituted
compounds
preparation
heteroaryl
indazol
Prior art date
Application number
PE2020001271A
Other languages
English (en)
Spanish (es)
Inventor
Sunil Kumar Kc
Chi Ching Mak
Gopi Kumar Mittapalli
Brian Joseph Hofilena
Brian Walter Eastman
Jianguo Cao
Chandramouli Chiruta
Venkataiah Bollu
Original Assignee
Samumed Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samumed Llc filed Critical Samumed Llc
Publication of PE20211447A1 publication Critical patent/PE20211447A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2020001271A 2018-02-23 2019-02-22 Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparacion y uso de las mismas PE20211447A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862634656P 2018-02-23 2018-02-23
PCT/US2019/019129 WO2019165192A1 (en) 2018-02-23 2019-02-22 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof

Publications (1)

Publication Number Publication Date
PE20211447A1 true PE20211447A1 (es) 2021-08-05

Family

ID=65812386

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001271A PE20211447A1 (es) 2018-02-23 2019-02-22 Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparacion y uso de las mismas

Country Status (18)

Country Link
US (2) US10934297B2 (cg-RX-API-DMAC7.html)
EP (1) EP3755696B1 (cg-RX-API-DMAC7.html)
JP (1) JP7369132B2 (cg-RX-API-DMAC7.html)
KR (1) KR102861944B1 (cg-RX-API-DMAC7.html)
CN (1) CN112020501A (cg-RX-API-DMAC7.html)
AU (1) AU2019224075A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020017087A2 (cg-RX-API-DMAC7.html)
CA (1) CA3091913A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002177A1 (cg-RX-API-DMAC7.html)
EA (1) EA202092002A1 (cg-RX-API-DMAC7.html)
ES (1) ES2945558T3 (cg-RX-API-DMAC7.html)
IL (1) IL276814A (cg-RX-API-DMAC7.html)
MA (1) MA51908A (cg-RX-API-DMAC7.html)
MX (1) MX2020008852A (cg-RX-API-DMAC7.html)
PE (1) PE20211447A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551300A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202008029UA (cg-RX-API-DMAC7.html)
WO (1) WO2019165192A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7369132B2 (ja) 2018-02-23 2023-10-25 サミュメッド リミテッド ライアビリティ カンパニー 5-ヘテロアリール置換イミダゾール-3-カルボキサミドならびにその調製および使用の方法
ES2913975T3 (es) * 2018-05-07 2022-06-07 Acraf Compuestos de 1H-indazol-3-carboxamida como inhibidores de la glucógeno sintasa cinasa-3 beta
JP7444458B2 (ja) * 2018-09-21 2024-03-06 学校法人福岡大学 プリオン病治療薬
US20250243181A2 (en) * 2019-12-16 2025-07-31 Korea Research Institute Of Chemical Technology Novel indazole derivative and use thereof
WO2021120890A1 (en) 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
EP4173673A1 (en) * 2021-10-26 2023-05-03 Perha Pharmaceuticals Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
KR20260040667A (ko) * 2023-06-14 2026-03-25 프로테나 바이오사이언시즈 리미티드 신경학적 장애 치료를 위한 바이시클릭 헤테로방향족 화합물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
GB0218625D0 (en) * 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
CA2499128C (en) 2002-09-25 2012-07-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
FR2845382A1 (fr) * 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
FR2867778B1 (fr) * 2004-03-16 2006-06-09 Sanofi Synthelabo Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
WO2005092890A2 (en) 2004-03-25 2005-10-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
UA93348C2 (ru) * 2004-03-25 2011-02-10 Меморі Фармас'Ютікалз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, их получение и применение
WO2011050245A1 (en) * 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
RU2014105624A (ru) * 2011-08-12 2015-09-20 Ф. Хоффманн-Ля Рош Аг Соединения индазола, способ их применения и фармацевтическая композиция
HUE041576T2 (hu) 2011-09-14 2019-05-28 Samumed Llc Indazol-3-karboxamid-származékok és alkalmazásuk Wnt/b-katenin szignalizáló útvonal inhibitorokként
EA024939B1 (ru) * 2012-02-21 2016-11-30 Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. 1h-индазол-3-карбоксамидные соединения в качестве ингибиторов гликогенсинтазы киназы 3-бета
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
BR112016021626A2 (pt) 2014-03-20 2018-05-15 Samumed, Llc indazol-3-carboxamidas 5-substituídas e preparação e uso das mesmas
WO2016040182A1 (en) * 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2017079759A1 (en) 2015-11-06 2017-05-11 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof
MY199242A (en) 2016-06-01 2023-10-22 Samumed Llc Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
BR112019008061A2 (pt) 2016-10-21 2019-09-17 Samumed Llc métodos de uso de indazol-3-carboxamidas e seu uso como inibidores da via de sinalização de wnt/b-catenina
JP7369132B2 (ja) 2018-02-23 2023-10-25 サミュメッド リミテッド ライアビリティ カンパニー 5-ヘテロアリール置換イミダゾール-3-カルボキサミドならびにその調製および使用の方法

Also Published As

Publication number Publication date
AU2019224075A1 (en) 2020-09-10
JP2021516674A (ja) 2021-07-08
EP3755696B1 (en) 2023-04-05
BR112020017087A2 (pt) 2020-12-22
SG11202008029UA (en) 2020-09-29
JP7369132B2 (ja) 2023-10-25
KR20200126393A (ko) 2020-11-06
CL2020002177A1 (es) 2021-01-08
CA3091913A1 (en) 2019-08-29
WO2019165192A1 (en) 2019-08-29
IL276814A (en) 2020-10-29
EA202092002A1 (ru) 2021-01-21
US20220402921A1 (en) 2022-12-22
MX2020008852A (es) 2020-10-14
MA51908A (fr) 2021-06-02
US11713320B2 (en) 2023-08-01
US10934297B2 (en) 2021-03-02
PH12020551300A1 (en) 2021-10-25
ES2945558T3 (es) 2023-07-04
KR102861944B1 (ko) 2025-09-26
CN112020501A (zh) 2020-12-01
EP3755696A1 (en) 2020-12-30
US20190263821A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
CR20220312A (es) Compuestos tricíclicos sustituidos
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
PE20230249A1 (es) Compuestos de heteroarilo biciclicos y usos de estos
PE20241068A1 (es) Moduladores de profarmacos de la via de estres integrada
EA202092558A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА ИНГИБИТОРА c-MET, ЕГО СОЛЕВАЯ ФОРМА И СПОСОБ ИХ ПОЛУЧЕНИЯ
CL2019003198A1 (es) Tienopiridinas y benzotiofenos útiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4).
CL2019003049A1 (es) Compuestos de heteroarilo bicíclicos 6-6 fusionados y su uso como inhibidores de lats.
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
CL2019002167A1 (es) Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.)
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
CL2020001343A1 (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
AR101177A1 (es) Inhibidores de la syk
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
EA201691731A1 (ru) Амидные соединения для лечения опосредованных комплементом нарушений
PE20181357A1 (es) Agentes inductores de apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
SV2016005229A (es) Inhibidores de syk
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR046272A1 (es) Inhibidores de dipeptidil peptidasa iv
PE20211769A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
PE20200756A1 (es) Compuestos de indazol como potenciadores alostericos mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica
AR096041A1 (es) Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg